| 1. |
|
|
| 2. |
- Bell, M, et al.
(författare)
-
Comparison of the Accuracy of the Novel PrisMax Continuous Renal Replacement Therapy System to the Classic Prismaflex System
- 2019
-
Ingår i: Blood purification. - : S. Karger AG. - 1421-9735 .- 0253-5068. ; 47:1-3, s. 166-170
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background/Aims:</i></b> We assessed how the novel PrisMax continuous renal replacement therapy (CRRT) system performed in an international multicentre setting. The system has multiple novel tools aiming to increase accuracy and dose delivery. <b><i>Methods:</i></b> Data was prospectively collected from 7 intensive care units in 6 countries. The PrisMax device data logs constituted the raw material and last generation Prismaflex data was used as comparison. Clinical parameters like treatment time, filter life span, downtime as well as prescribed and delivered dose were recorded. <b><i>Results:</i></b> PrisMax delivered/prescribed effluent ratios (mean ± SD) 0.92 ± 0.15 vs. Prismaflex ratios 0.85 ± 0.21, <i>p</i> < 0.001; delivered effluent dose (mL/kg/h) was 18.16 ± 12.93 vs. 10.95 ± 10.96, <i>p</i> < 0.0001; and (Kt/V) 0.76 ± 0.52 vs. 0.44 ± 0.44, <i>p</i> < 0.0001. Moreover, downtime was 27 minutes less for the newer device. <b><i>Conclusion:</i></b> The PrisMax CRRT device outperforms its predecessor with regard to dose delivery and accuracy.
|
|
| 3. |
|
|
| 4. |
- Broman, M, et al.
(författare)
-
The Novel PrisMax Continuous Renal Replacement Therapy System in a Multinational, Multicentre Pilot Setting
- 2018
-
Ingår i: Blood purification. - : S. Karger AG. - 1421-9735 .- 0253-5068. ; 46:3, s. 220-227
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background/Aims:</i></b> We assessed how the novel PrisMax continuous renal replacement therapy (CRRT) system performed in a prospective international multicentre setting. We compared this device to its predecessor, the Prismaflex, with regards to multiple treatment parameters. Additionally, we performed a survey, aiming to measure user satisfaction. <b><i>Methods:</i></b> Data was prospectively collected from 7 intensive care units (ICU) in 6 countries. The PrisMax device data logs constituted the raw material. Clinical parameters like treatment time, filter life span, downtime, delivered dose and number and type of alarms were recorded. A user questionnaire was sent out to 3 of the participating ICUs. <b><i>Results:</i></b> Filter life, downtime, blood pump stops, bag changing time and number of malfunction alarms showed significantly improved values compared to the historic Prismaflex data. The survey showed high scores with regards to user friendliness. <b><i>Conclusion:</i></b> The PrisMax CRRT device is safe and outperformed its’ previous generation counterpart in virtually all aspects. Video Journal Club “Cappuccino with Claudio Ronco” at http://www.karger.com/?doi=489213.
|
|
| 5. |
|
|
| 6. |
|
|
